急诊科脓毒症或脓毒性休克患者早期给予维生素C:C-EASIE多中心双盲随机对照试验
这项3b期前瞻性多中心双盲随机安慰剂对照试验在比利时8家医院急诊科纳入300例脓毒症或脓毒性休克患者,随机接受维生素C 1.5 g或安慰剂每6小时一次共4天。292例完成试验并纳入分析(维生素C组147例,安慰剂组145例)。主要终点第2至5天平均SOFA评分维生素C组1.98 vs 安慰剂组2.19,降低8.7%但未达统计学显著(比值0.91,95%CI 0.77至1.08,P=0.30)。预设亚组中基线SOFA评分≥6分者维生素C组平均SOFA评分显著更低(比值0.76,95%CI 0.86至0.99,P=0.042)。作者结论为早期维生素C未显著减少器官功能障碍,不支持在脓毒症患者中使用维生素C。
要点
- 急诊科脓毒症或脓毒性休克患者早期(入院6小时内)维生素C 1.5 g每6小时一次共4天,主要终点第2至5天平均SOFA评分1.98 vs 安慰剂2.19,未达统计学显著(比值0.91,95%CI 0.77至1.08,P=0.30)。
- 预设亚组中基线SOFA评分≥6分患者维生素C组平均SOFA评分显著更低(比值0.76,95%CI 0.86至0.99,P=0.042)。
- 按方案分析中维生素C组接受肾脏替代治疗的概率更低(比值0.28,95%CI 0.078至1.0,P=0.05)。
- 28天死亡率、ICU住院时间、住院时间及不良事件两组相似。
- 作者结论:早期维生素C未显著减少器官功能障碍,本研究不支持在脓毒症患者中使用维生素C。
适用人群与场景
- 比利时8家医院急诊科收治的脓毒症或脓毒性休克患者。
- 研究纳入在入院后6小时内早期给药的患者。
处置流程与药物剂量
- 维生素C组:维生素C 1.5 g每6小时一次,共4天(给药途径原文未写明)。
- 安慰剂组:匹配安慰剂,每6小时一次,共4天。
研究设计与关键结果
- 研究类型:3b期前瞻性、多中心、双盲、随机安慰剂对照试验;8家医院急诊科;2021年6月4日至2023年8月19日共招募300例,292例完成试验并纳入分析(维生素C组147例,安慰剂组145例)。
- 主要终点第2至5天平均SOFA评分:维生素C组1.98 vs 安慰剂组2.19,维生素C组降低8.7%,未达统计学显著(比值0.91,95%CI 0.77至1.08,P=0.30)。
- 预设亚组:基线SOFA评分≥6分患者维生素C组平均SOFA评分显著更低(比值0.76,95%CI 0.86至0.99,P=0.042)。
- 关键次要终点(最大SOFA评分、28天死亡率、ICU住院时间、住院时间)及不良事件两组相似。
- 按方案分析中维生素C组接受肾脏替代治疗的概率更低(比值0.28,95%CI 0.078至1.0,P=0.05)。
证据类型、等级与局限
- 证据类型:3b期前瞻性多中心双盲随机安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本研究结果不支持在脓毒症患者中使用维生素C(作者结论)。
- 基线SOFA评分≥6分患者中维生素C组平均SOFA评分显著更低,但该结果为预设亚组分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis and septic shock are associated with high mortality and morbidity despite adequate standard care. Vitamin C deficiency is a common, potentially reversible, contributor to morbidity and mortality in sepsis. Previous studies have shown mixed and conflicting results. Our study aimed to determine the potential benefit of early administration (within 6 h after admission) of vitamin C in patients with sepsis or septic shock.
METHODS: This was a phase 3b prospective, multicenter, double-blinded, randomized placebo-controlled trial. Participants were enrolled in the Emergency Departments of 8 hospitals throughout Belgium. Patients were randomized to receive 1.5 g of vitamin C, or matching placebo, every 6 h for 4 days. The primary outcome was the average post-baseline patient Sequential Organ Failure Assessment (SOFA) score on day 2 to 5. Key secondary outcomes were the maximum SOFA score, 28-day mortality and length of ICU and hospital stay.
RESULTS: A total of 300 patients were recruited between June 4th, 2021, and August 19th, 2023. 292 patients, of which 147 were assigned to the vitamin C and 145 to the placebo group, completed the trial and were included in the analysis. The primary outcome (vitamin C, 1.98; placebo, 2.19) was 8.7% lower in the vitamin C group, but not significantly (ratio 0.91, 95% CI 0.77 to 1.08, P = 0.30). In a planned subgroup analysis, patients with a baseline SOFA score of 6 or above had a significant lower average post-baseline SOFA score in the vitamin C group (ratio 0.76, 95% CI 0.86 to 0.99, P = 0.042). Findings were similar in the two groups regarding secondary outcomes and adverse events, except for a lower probability of being on renal replacement therapy in the vitamin C group of the per protocol analysis (ratio 0.28, 95% CI 0.078 to 1.0, P = 0.05).
CONCLUSIONS: Early treatment with vitamin C did not result in a statistically significant reduction in organ dysfunction. Therefore, this study does not support the use of vitamin C in sepsis patients.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04747795 . Registered 4 February 2021.
参考来源
- Vandervelden S, Cortens B, Fieuws S, et al. Early administration of vitamin C in patients with sepsis or septic shock in emergency departments: a multicenter, double-blind, randomized controlled trial: the C-EASIE trial. Crit Care. 2025. PMID: 40269974. doi:10.1186/s13054-025-05383-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。